These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 34488664)

  • 1. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.
    Plum PE; Maes N; Sauvage AS; Frippiat F; Meuris C; Uurlings F; Lecomte M; Léonard P; Paquot N; Fombellida K; Vaira D; Moutschen M; Darcis G
    BMC Infect Dis; 2021 Sep; 21(1):910. PubMed ID: 34488664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
    Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
    Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
    Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
    J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization.
    Brunet L; Mallon P; Fusco JS; Wohlfeiler MB; Prajapati G; Beyer A; Fusco GP
    Clin Drug Investig; 2021 Nov; 41(11):955-965. PubMed ID: 34546533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain.
    Kauppinen KJ; Aho I; Sutinen J
    AIDS; 2022 Aug; 36(10):1337-1344. PubMed ID: 35727143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
    Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group.
    Łomiak M; Stępnicki J; Mikuła T; Wiercińska-Drapało A
    Int J STD AIDS; 2021 May; 32(6):570-577. PubMed ID: 33612018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan.
    Kanda N; Okamoto K; Okumura H; Mieno M; Sakashita K; Sasahara T; Hatakeyama S
    HIV Med; 2021 Jul; 22(6):457-466. PubMed ID: 33720508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting.
    Kauppinen KJ; Kivelä P; Sutinen J
    AIDS Patient Care STDS; 2019 Dec; 33(12):500-506. PubMed ID: 31742421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
    Sarowar A; Coffin CS; Fung S; Wong A; Doucette K; Truong D; Conway B; Haylock-Jacobs S; Ramji A; Hansen BE; Janssen HLA; Cooper C
    J Acquir Immune Defic Syndr; 2022 Dec; 91(4):368-372. PubMed ID: 36288543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
    Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
    Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data.
    Tabak F; Zerdali E; Altuntaş O; Gunduz A; Bolukcu S; Mete B; Nakir IY; Kumbasar Karaosmanoglu H; Yildiz DS; Meric Koc M; Dokmetas İ;
    Int J STD AIDS; 2021 May; 32(6):562-569. PubMed ID: 33599173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.
    Sjaarda A; Bernstein A; Sparks A; Saber S; Siegel M
    Infection; 2022 Apr; 50(2):407-412. PubMed ID: 34449049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back.
    Milinkovic A; Berger F; Arenas-Pinto A; Mauss S
    AIDS; 2019 Dec; 33(15):2387-2391. PubMed ID: 31764103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide.
    Schafer JJ; Zimmerman M; Walshe C; Cerankowski J; Shimada A; Keith SW
    Obesity (Silver Spring); 2022 Jun; 30(6):1197-1204. PubMed ID: 35674696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
    Sun L; He Y; Xu L; Zhao F; Zhou Y; Zhang L; Peng Q; Zhang H; Zhang Q; Cao T; Song Y; Wang S; Rao M; Jia X; Liu X; Zhou J; Ju B; Wang H; Liu J
    J Acquir Immune Defic Syndr; 2022 Oct; 91(S1):S8-S15. PubMed ID: 36094509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study.
    Martínez-Sanz J; Serrano-Villar S; Muriel A; García Fraile LJ; Orviz E; Mena de Cea Á; Campins AA; Moreno S
    Clin Infect Dis; 2023 Feb; 76(3):e652-e660. PubMed ID: 35903910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV.
    Lacey A; Savinelli S; Barco EA; Macken A; Cotter AG; Sheehan G; Lambert JS; Muldoon E; Feeney E; Mallon PW; Tinago W;
    AIDS; 2020 Jul; 34(8):1161-1170. PubMed ID: 32310899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIV.
    Damas J; Munting A; Fellay J; Haerry D; Marzolini C; Tarr PE; Steffen A; Braun DL; Stoeckle M; Bernasconi E; Nawej Tshikung O; Fux CA; Darling KEA; Béguelin C; Wandeler G; Cavassini M; Surial B;
    Clin Infect Dis; 2024 Oct; 79(4):990-998. PubMed ID: 38606792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B.
    Cheng PN; Feng IC; Chen JJ; Kuo HT; Lee PL; Yu ML; Chiu YC; Chiu HC; Chien SC; Chen PJ; Liu CJ
    Aliment Pharmacol Ther; 2024 Jan; 59(2):230-238. PubMed ID: 37845815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.